RecruitingNot ApplicableNCT07572513

Slowly Digestible Carbohydrates for GLP-1 Secretion


Sponsor

Purdue University

Enrollment

19 participants

Start Date

May 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trail is to learn if the hormone, glucagon-like peptide-1 (GLP-1), is stimulated by slowly digestible carbohydrates (SDCs) in healthy adults. In the current study, researchers will observe the amount of SDC that results in clinically meaningful levels of GLP-1, shown by an increase in feelings of fullness and a decrease in hunger, and how long an elevated level of GLP-1 lasts after starch consumption. Researchers aim to address two questions: What amount of SDC maximizes GLP-1-mediated satiety, and does the impact to satiety continue in a second meal? The overall goal is to maximize ileal-digesting SDC's potential use as a food-based agent for weight loss. Researchers will compare 20, 40, and 60 g of raw corn starch compared to a maltodextrin control on total plasma GLP-1 concentrations, insulin, and blood glucose at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Researchers will also measure satiety at baseline, 60, 120, 180 minutes and after a second meal. There will be a total of 4 study visits with a least a 7-day break between visits. At each study visit, participants will: * Consume a randomized test beverage (SDC or maltodextrin) * Receive a blood draw at 7 timepoints over 3 hrs * Take a satiety questionnaire 5 times over 3 hrs * Consume a standardized lunch 3 hrs after the test beverage consumption


Eligibility

Min Age: 18 YearsMax Age: 45 Years

Inclusion Criteria7

  • Healthy population
  • BMI between 18.5 and 24.9 kg/m2
  • Adults 18 - 45 years old
  • Men or women
  • Able to read/speak English
  • Fasting blood glucose levels ≤100 mg/dL
  • HbA1c ≤ 5.7%

Exclusion Criteria7

  • Participants with 18 > Years of Age > 45 will be excluded.
  • Subjects with 18.5 kg/m² > BMI > 24.9 kg/m² will be excluded.
  • Diabetic individuals will be excluded.
  • Individuals with history of gastrointestinal disease will be excluded from the study.
  • Pregnant or nursing women will also be excluded.
  • Individuals taking GLP-1 medications, or on weight-loss diets or restrictive eating patterns.
  • Individuals suffering from dairy or gluten intolerance or allergies will be excluded.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTMaltodextrin (Placebo)

75 g of maltodextrin diluted in 200 mL of water, taken once at a study visit

DIETARY_SUPPLEMENTRaw Corn Starch

Quantity of raw corn starch will vary between low, medium, and high-dose treatment arms (20, 40, 60 g respectively). Each treatment will total 75 g using maltodextrin to account for mass difference (55, 35, 15 g respectively).


Locations(1)

Clinical Research Center at Purdue University

West Lafayette, Indiana, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07572513


Related Trials